Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Free Cash Flow data on file, last reported at -$32.7 million in Q1 2026.

• Quarterly Free Cash Flow fell 28.29% year-over-year to -$32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.4 million (down 38.9% YoY) and the FY2025 annual result came in at -$95.2 million, down 35.17% from the prior year.
• Free Cash Flow slipped to -$32.7 million in Q1 2026, from -$23.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$9.2 million in Q1 2022 to a low of -$32.7 million in Q1 2026.
• A 5-year average of -$17.6 million and a median of -$17.3 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 274.6% — and 2023, when it soared 43.01%.
• Tracing TYRA's Free Cash Flow over 5 years: stood at -$12.0 million in 2022, then dropped by 18.08% to -$14.1 million in 2023, then slumped by 38.63% to -$19.6 million in 2024, then declined by 20.77% to -$23.7 million in 2025, then plunged by 37.99% to -$32.7 million in 2026.
• The last three Free Cash Flow figures came in at -$32.7 million (Q1 2026), -$23.7 million (Q4 2025), and -$22.4 million (Q3 2025), per Business Quant data.